BCRX - BioCryst Pharmaceuticals Inc

BCRX - BioCryst Pharmaceuticals Inc

https://www.biocryst.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 week, 5 days ago • score: 0.27

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and ...

BioCryst to Present at Upcoming Investor Conference - BioCryst Pharma ( NASDAQ:BCRX )

Benzinga • 3 weeks, 4 days ago • score: 0.30

RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire • 3 weeks, 4 days ago • score: 0.31

RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.

Are Options Traders Betting on a Big Move in BCRX Stock?

Zacks Commentary • 1 month ago • score: 0.15

Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.

BioCryst Announces Departure of Dr. Helen Thackray - BioCryst Pharma ( NASDAQ:BCRX )

Benzinga • 1 month ago • score: 0.19

RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 month, 1 week ago • score: 0.28

RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.

52W High

$11.31

52W Low

$6.01

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.13

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

22.99

EV/EBITDA (<8 favorable)

34.35

EV/Revenue (<3 favorable)

3.91

P/S (TTM) (<3 favorable)

3.11

P/B (<3 favorable)

56.59

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.26%

Institutions (25–75% balanced)

95.42%

Shares Outstanding

209,920,000

Float

207,687,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

557,506,000

Gross Profit (TTM)

370,642,000

EPS (TTM)

-0.18

Profit Margin (>10% good)

-0.06%

Operating Margin (TTM) (higher better)

0.18%

ROE (TTM) (>15% strong)

-19.25%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.49

Momentum

Bearish momentum

Value

-0.1655

Previous

-0.1453

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025